rethinkTHC Search
Menu
Study breakdown

CBD reduced brain inflammation and reversed schizophrenia-like behaviors in mice, matching the effects of clozapine

Animal StudyPreliminary evidence
The takeaway

Repeated CBD treatment reversed social withdrawal, cognitive deficits, and brain inflammation (activated microglia and astrocytes) in a mouse model of schizophrenia, performing comparably to the antipsychotic clozapine.

Read this if you're interested in how CBD might work differently from traditional antipsychotics.

CBD matched clozapine in reversing behavioral and glial changes

What the researchers found

Researchers used an animal model of schizophrenia based on blocking NMDA receptors (which mimics the glutamate dysfunction seen in schizophrenia) and tested whether CBD could reverse the resulting behavioral and brain changes.

Chronic MK-801 treatment impaired social interaction and novel object recognition in mice, modeling the negative symptoms and cognitive deficits of schizophrenia. It also increased reactive astrocytes in the prefrontal cortex and activated microglia (inflammatory brain cells) in the prefrontal cortex and hippocampus.

Repeated CBD treatment (30 and 60 mg/kg) reversed both the behavioral impairments and the inflammatory glial changes. CBD's effects were comparable to those of clozapine, an established antipsychotic. The findings suggest CBD's antipsychotic-like effects may work through its anti-inflammatory and neuroprotective properties.

Why it matters

Current antipsychotics have significant side effects and poorly treat negative symptoms and cognitive deficits. If CBD can address these through anti-inflammatory mechanisms, it could offer a complementary or alternative approach with a better side effect profile.

The numbers in context

CBD tested at 30 and 60 mg/kg. 5 brain regions examined. GFAP-positive astrocytes increased in mPFC by MK-801. Reactive microglia increased in mPFC and dorsal hippocampus. Both behavioral and glial changes reversed by CBD and clozapine. No neuron loss observed.

How the study worked

Controlled animal study using chronic MK-801 (NMDA antagonist) administration for 28 days to model schizophrenia. CBD (30 and 60 mg/kg) and clozapine were given as repeated treatments. Social interaction and novel object recognition tests assessed behavior. Immunohistochemistry measured NeuN, Iba-1, and GFAP expression across 5 brain regions.

What this study cannot tell us

Mouse model does not fully replicate human schizophrenia. NMDA antagonist models capture some but not all aspects of the disorder. CBD doses may not translate directly to human dosing. Long-term effects and safety of repeated CBD in this context are not established.

How to read the evidence

Controlled animal study with comprehensive behavioral and molecular assessments. No human data for this specific mechanism.

When this study was published

Published in 2015. CBD for psychosis research has progressed to human clinical trials.

The bigger picture

The link between neuroinflammation and schizophrenia is gaining attention. If CBD's antipsychotic effects are mediated through reducing brain inflammation rather than blocking dopamine, it represents a fundamentally different therapeutic approach to psychotic disorders.

Questions still open

  • Would CBD be effective as an adjunct to current antipsychotics in humans? Does the anti-inflammatory mechanism explain CBD's effects in human psychosis trials? Could CBD prevent the neuroinflammatory changes that precede psychotic symptoms?

Common questions

Could CBD treat schizophrenia?
In this mouse study, CBD reversed behaviors that model negative symptoms and cognitive deficits of schizophrenia and reduced brain inflammation. Human clinical trials of CBD for psychosis are underway but definitive evidence is still building.
How might CBD work as an antipsychotic?
Unlike traditional antipsychotics that block dopamine, this study suggests CBD may work by reducing brain inflammation, specifically by dampening reactive astrocytes and microglia. This is a fundamentally different mechanism.

Read the original research

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.

Schizophrenia research, 164(1-3), 155-63

Citation

Gomes, Felipe V; Llorente, Ricardo; Del Bel, Elaine A; Viveros, Maria-Paz; López-Gallardo, Meritxell; Guimarães, Francisco S. (2015). Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.. Schizophrenia research, 164(1-3), 155-63. https://doi.org/10.1016/j.schres.2015.01.015

Explore the wider topic